Symbio Pharmaceuticals Limited (JP:4582)
:4582
Top Page
Symbio Pharmaceuticals Limited
(4582)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥104.00
▲(15.56% Upside)
Action:ReiteratedDate:03/17/26
The score is primarily held down by weakened financial performance—multi-year revenue declines, deep losses, heavy cash burn, and increased leverage with equity erosion. Technicals are mixed with neutral-to-oversold signals providing only limited support, while valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
Niche specialty focus
A clear focus on oncology and hematology targets unmet medical needs where demand and pricing power tend to be more durable. Specialization supports deeper clinical expertise, stronger payer/physician relationships, and makes the company a more attractive partner for licensing and co-commercialization over the medium term.
Negative Factors
Multi-year revenue decline
Sustained top-line contraction reduces scale and weakens the company's ability to cover fixed costs, invest in trials, and support commercialization. Continued declines undermine partner confidence and can lead to a durable erosion of market position unless new revenue sources emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Niche specialty focus
A clear focus on oncology and hematology targets unmet medical needs where demand and pricing power tend to be more durable. Specialization supports deeper clinical expertise, stronger payer/physician relationships, and makes the company a more attractive partner for licensing and co-commercialization over the medium term.
Read all positive factors
Symbio Pharmaceuticals Limited (4582) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.07B
Dividend YieldN/A
Average Volume (3M)577.10K
Price to Earnings (P/E)―
Beta (1Y)0.85
Revenue Growth-50.27%
EPS Growth-3.33%
CountryJP
Employees108
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-21.66
Shares Outstanding59,567,080
10 Day Avg. Volume434,010
30 Day Avg. Volume577,100
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)3.55
Price to Sales (P/S)3.46
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Symbio Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cance...
How the Company Makes Money
Symbio Pharmaceuticals generates revenue primarily from the sale of its pharmaceutical products in Japan once they are approved and launched. In addition, the company’s business model commonly involves licensing arrangements: it in-licenses drug r...
Symbio Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.82B | 1.31B | 2.45B | 5.59B | 10.01B | 8.25B |
| Gross Profit | 1.37B | 947.34M | 1.87B | 4.41B | 7.60B | 5.80B |
| EBITDA | -4.61B | -4.60B | -3.78B | -714.00M | 2.06B | 1.11B |
| Net Income | -4.66B | -4.78B | -3.83B | -1.96B | 1.18B | 2.03B |
Balance Sheet | ||||||
| Total Assets | 4.14B | 3.87B | 4.97B | 8.17B | 17.43B | 15.18B |
| Cash, Cash Equivalents and Short-Term Investments | 3.05B | 2.88B | 3.96B | 6.52B | 6.28B | 3.86B |
| Total Debt | 1.30B | 1.98B | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.78B | 2.60B | 770.77M | 8.14B | 8.92B | 8.43B |
| Stockholders Equity | 2.36B | 1.27B | 4.20B | 7.21B | 8.51B | 6.75B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -4.58B | -3.44B | -427.48M | 1.57B | 76.20M |
| Operating Cash Flow | 0.00 | -4.58B | -3.42B | -194.69M | 1.61B | 140.04M |
| Investing Cash Flow | 0.00 | -75.92M | -3.96M | -376.70M | -47.13M | -70.85M |
| Financing Cash Flow | 0.00 | 3.62B | 708.47M | 680.16M | 627.99M | -71.92M |
Symbio Pharmaceuticals Limited Technical Analysis
Negative
90.00
Price Trends
114.36
Negative
105.90
Positive
127.75
Negative
Market Momentum
-3.10
Positive
44.16
Neutral
3.92
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 90 is below the 20-day moving average (MA) of 113.95, below the 50-day MA of 114.36, and below the 200-day MA of 127.75, indicating a bearish trend. The MACD of -3.10 indicates Positive momentum. The RSI at 44.16 is Neutral, neither overbought nor oversold. The STOCH value of 3.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.
Symbio Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥14.87B | 16.22 | ― | ― | -5.41% | ― | |
64 Neutral | ¥6.23B | 11.64 | ― | 3.21% | 4.25% | ― | |
53 Neutral | ¥9.28B | -13.67 | -90.96% | ― | 243.16% | -23.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥11.94B | 7.11 | ― | 1.06% | 5.42% | -62.03% | |
43 Neutral | ¥6.07B | -0.95 | ― | ― | -50.27% | -3.33% | |
42 Neutral | ¥5.11B | -10.38 | ― | ― | -52.41% | -80.31% |
* Healthcare Sector Average
JP:4582
Symbio Pharmaceuticals Limited
102.00
-42.00
-29.17%
JP:4597
Solasia Pharma KK
34.00
2.00
6.25%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
344.00
37.58
12.27%
JP:4539
Nippon Chemiphar Co., Ltd.
1,725.00
317.98
22.60%
JP:4574
Taiko Pharmaceutical Co., Ltd.
297.00
36.00
13.79%
JP:4586
Medrx Co., Ltd.
86.00
24.00
38.71%
Symbio Pharmaceuticals Limited Corporate Events
SymBio Pharmaceuticals’ Losses Deepen as Equity Thins Despite 2026 Sales Rebound Forecast
Feb 5, 2026
SymBio Pharmaceuticals reported a steep decline in consolidated net sales for fiscal 2025 to ¥1.31 billion, down 46.7% year-on-year, alongside widening operating and net losses, with profit attributable to owners of parent falling to a loss o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.